Juniper Pharmaceuticals Inc  

(Public, NASDAQ:JNP)   Watch this stock  
Find more results for P.M. Smith´┐Ż
8.03
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.09 - 8.40
Open     -
Vol / Avg. 0.00/19,674.00
Mkt cap 86.52M
P/E 34.98
Div/yield     -
EPS 0.23
Shares 10.78M
Beta 1.04
Inst. own 26%
Jul 29, 2015
Q2 2015 Juniper Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jul 6, 2015
Juniper Pharmaceuticals Annual Shareholder Meeting - 8:00PM EDT - Add to calendar
Jun 4, 2015
Juniper Pharmaceuticals Inc at Jefferies Global Healthcare Conference - 1:00PM EDT - Add to calendar
May 28, 2015
Juniper Pharmaceuticals Inc at Marcum MicroCap Conference
May 6, 2015
Q1 2015 Juniper Pharmaceuticals Inc Earnings Release
May 6, 2015
Q1 2015 Juniper Pharmaceuticals Inc Earnings Call
Mar 18, 2015
Q4 2014 Columbia Laboratories Inc Earnings Call
Mar 18, 2015
Q4 2014 Columbia Laboratories Inc Earnings Release
Mar 11, 2015
Columbia Laboratories Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -8.31% 10.44%
Operating margin -9.98% 11.75%
EBITD margin - 18.22%
Return on average assets -5.41% 6.04%
Return on average equity -6.89% 7.66%
Employees 85 -
CDP Score - -

Address

4 Liberty Sq Fl 4
BOSTON, MA 02109-4811
United States - Map
+1-973-4868820 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Juniper Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health. Juniper develops pharmaceutical products, including CRINONE 8% (progesterone gel), which is marketed by Actavis, Inc. in the United States and by Merck Serono S.A. in over 60 countries worldwide. The Company has in-house pharmaceutical development, clinical trial manufacturing, and analytical capabilities to advance an internal development pipeline, while also providing consultative services to its pharmaceutical industry customers. Juniper Pharmaceuticals and Juniper Pharma Services are trademarks of the Company in the United States and European Union. CRINONE is a trademark of Actavis, Inc. in the United States.

Officers and directors

Stephen Garfield Kasnet Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Frank C. Condella Jr. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
George O. Elston CPA Chief Financial Officer, Treasurer, Secretary
Age: 50
Bio & Compensation  - Reuters
Nikin Patel Chief Operating Officer, Director
Age: 41
Bio & Compensation  - Reuters
Shen Luk Ph.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Claire Madden-Smith Ph.D. Vice President - Commercial Services
Bio & Compensation  - Reuters
Bridget A. Martell Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
James A. Geraghty Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Donald H. Hunter Director
Age: 58
Bio & Compensation  - Reuters
Valerie L. Andrews Independent Director
Age: 55
Bio & Compensation  - Reuters